Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 10:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 969 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Group Regimen Clear all
Completed Phase 3 Interventional

Peri-operative Oral Pain Control Following Buccal Graft Urethroplasty

NCT05300685
View directory record Official record
Conditions
Urethral Stricture, Male
Interventions
Standard Buccal Harvest, Basic buccal procedure + Long acting local, Basic buccal procedure + Buccal block
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
San Francisco, California • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 26, 2026, 10:22 PM EDT
Terminated Phase 2 Interventional

Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis

NCT05048056
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Placebo, AK120
Drug
Lead sponsor
Akesobio Australia Pty Ltd
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
16
States / cities
Little Rock, Arkansas • Canoga Park, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Oct 26, 2026, 10:22 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

International PPB/DICER1 Registry

NCT03382158
View directory record Official record
Conditions
Pleuropulmonary Blastoma, Sertoli-Leydig Cell Tumor, DICER1 Syndrome, Cystic Nephroma, Wilms Tumor, Pineoblastoma, Renal Sarcoma, Nodular Hyperplasia of Thyroid, Nasal Chondromesenchymal Hamartoma, Ciliary Body Medulloepithelioma, Neuroblastoma, Pituitary Cancer, Embryonal Rhabdomyosarcoma, Ovarian Sarcoma, Gynandroblastoma, Thyroid Carcinoma, Embryonal Rhabdomyosarcoma of Vagina (Diagnosis), Embryonal Rhabdomyosarcoma of Uterus (Diagnosis), Embryonal Rhabdomyosarcoma of Cervix, Intracranial Sarcoma
Interventions
Not listed
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
0 Minutes to 100 Years
Enrollment
3,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2036
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 26, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Results available

IDegLira HIGH Trial

NCT03737240
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
IDegLira, Insulin Degludec (U-100), Insulin Aspart
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 8, 2023 · Synced Oct 26, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease

NCT02760407
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Olokizumab 64mg q4w, Olokizumab 64mg q2w, Adalimumab 40mg q2w, Placebo q2w
Drug
Lead sponsor
R-Pharm International, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,648 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
64
States / cities
Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 26, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine

NCT02629861
View directory record Official record
Conditions
Migraine
Interventions
Fremanezumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
875 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
178
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 77 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 26, 2026, 10:22 PM EDT
Recruiting Not applicable Interventional

Vestibular Therapy in Alzheimer's Disease

NCT03799991
View directory record Official record
Conditions
Vestibular Diseases, Vestibular Disorder, Alzheimer Disease
Interventions
Vestibular physical therapy, Active control
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
60 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 26, 2026, 10:22 PM EDT
Withdrawn Not applicable Interventional

Dynamic Splinting for Excessive Pronation Following CVA

NCT00900692
View directory record Official record
Conditions
Pronation Contracture
Interventions
Dynasplint
Device
Lead sponsor
Dynasplint Systems, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Oct 26, 2026, 10:22 PM EDT
Completed Not applicable Interventional Results available

Robotic Walking Device to Improve Mobility in Parkinson's Disease

NCT03751371
View directory record Official record
Conditions
Parkinson Disease
Interventions
Training with HWA device, Usual Care
Device · Other
Lead sponsor
Ohio State University
Other
Eligibility
50 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 26, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors

NCT02622321
View directory record Official record
Conditions
Hemophilia A
Interventions
Emicizumab, rFVIIa, aPCC
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
11
States / cities
Los Angeles, California • Santa Monica, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Oct 26, 2026, 10:22 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Different Combinations of Zonisamide-CR Plus Bupropion-SR to Treat Uncomplicated Obesity

NCT00339014
View directory record Official record
Conditions
Obesity
Interventions
Zonisamide CR and Bupropion SR, Placebo
Drug · Other
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
15
States / cities
Fairhope, Alabama • Los Angeles, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2008 · Synced Oct 26, 2026, 10:22 PM EDT
Completed Not applicable Interventional

Preventing Falls Through Enhanced Pharmaceutical Care

NCT00618800
View directory record Official record
Conditions
Falls
Interventions
Pharmaceutical Care, Written Materials
Behavioral · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
65 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 19, 2011 · Synced Oct 26, 2026, 10:22 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Effects of Emixustat Hydrochloride in Subjects With Proliferative Diabetic Retinopathy

NCT02753400
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy
Interventions
emixustat hydrochloride, Placebo
Drug · Other
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 26, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.

NCT01197534
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
fostamatinib, placebo, fostamatinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
913 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
57
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2014 · Synced Oct 26, 2026, 10:22 PM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety and Pharmacokinetics of Different Regimens of Indacaterol

NCT01156844
View directory record Official record
Conditions
Persistent Asthma
Interventions
Indacaterol, Placebo to Indacaterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
21
States / cities
Anniston, Alabama • Cypress, California • Fresno, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2011 · Synced Oct 26, 2026, 10:22 PM EDT
Withdrawn Not applicable Interventional

Exercise Training Among Men With Prostate Cancer

NCT00620932
View directory record Official record
Conditions
Prostatectomy
Interventions
Exercise
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 28, 2013 · Synced Oct 26, 2026, 10:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Wayfinding Intervention in High-Fidelity Long-Term Memory

NCT04253587
View directory record Official record
Conditions
Long-Term Memory Decline, Mild Cognitive Impairment
Interventions
LabyrinthVR, Placebo Games, Coherence, Tablet
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
62 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Oct 26, 2026, 10:22 PM EDT
Completed Phase 4 Interventional Results available

Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension

NCT00931710
View directory record Official record
Conditions
Stage 2 Systolic Hypertension
Interventions
valsartan, amlodipine, HCTZ, Losartan, HCTZ followed by valsartan, amlodipine, HCTZ
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 7, 2011 · Synced Oct 26, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Results available

Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)

NCT02345850
View directory record Official record
Conditions
Acute Leukemia, Myelodysplasia
Interventions
Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate, Mobilized CD34-selected Peripheral Blood Stem Cell graft, Unmanipulated Bone Marrow Graft with Cyclophosphamide, Cyclophosphamide, Tacrolimus, Methotrexate
Procedure · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
1 Year to 65 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
28
States / cities
Duarte, California • Stanford, California • Gainesville, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Oct 26, 2026, 10:22 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy

NCT01813019
View directory record Official record
Conditions
Patient Diagnosed With OCD and Resistant to SSRI Treatment, Failed SSRI Over 12 Weeks at Appropriate Doses
Interventions
AFQ056, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
San Diego, California • Watertown, Massachusetts • Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jan 2, 2017 · Synced Oct 26, 2026, 10:22 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

NCT06824181
View directory record Official record
Conditions
Pneumococcal Immunization
Interventions
PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine, Rotarix, RotaTeq, Vaxelis vaccine, Varivax, Priorix, VAQTA, Havrix
Biological
Lead sponsor
Sanofi
Industry
Eligibility
42 Days to 89 Days
Enrollment
580 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
17
States / cities
Los Angeles, California • Hollywood, Florida • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 26, 2026, 10:22 PM EDT
Recruiting Phase 3 Interventional

The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation

NCT05836987
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
AFSW Guided DOAC, Continuous DOAC therapy
Device · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
22 Years to 85 Years
Enrollment
5,350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
93
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 68 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 26, 2026, 10:22 PM EDT
Terminated Phase 3 Interventional Results available

Everolimus Monotherapy as Immunosuppression After Liver Transplant

NCT04063865
View directory record Official record
Conditions
Kidney Failure
Interventions
Tacrolimus, Everolimus
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Oct 26, 2026, 10:22 PM EDT
Completed Phase 4 Interventional

Staph Intervention for Effective Local Defense

NCT06210594
View directory record Official record
Conditions
Staphylococcus Aureus Infection
Interventions
Mupirocin + Nozin + chlorhexidine gluconate, Education + Household supplies
Combination Product · Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Whiteriver, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 26, 2026, 10:22 PM EDT